Drugs made with iPS, or induced pluripotent stem cells, will be used to treat patients with severe heart failure and Parkinson’s disease
Induced pluripotent stem cells, or iPS, were generated by Yamanaka, who announced the generation of mouse iPS cells in 2006 and human iPS cells in 2007. He won the Nobel Prize in Physiology or Medicine in 2012.
With ReHeart, heart muscle sheets derived from human iPS cells are placed on the surface of the heart, where they promote the formation of new blood vessels underneath and help restore heart function.
Patients with severe heart disease are often given medicine to prevent deterioration and sometimes may have to undergo a heart transplant.
